Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia

Neuroscience

Volumn 119, Issue 2, 2003, Pages 547-555

  McCormick, S E ^a   Stoessl, A J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Globus pallidus; Neurotensin; Non opioid peptides; Striatum; Substantia nigra pars reticulata

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; DIMETHYL SULFOXIDE; FLUPHENAZINE DECANOATE; MESSENGER RNA; NEUROLEPTIC AGENT; NEUROTENSIN; SESAME SEED OIL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANNULATION; CORPUS STRIATUM; DRUG EFFECT; DRUG INFUSION; GLOBUS PALLIDUS; MALE; MASTICATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SUBSTANTIA NIGRA; SURGICAL TECHNIQUE; TARDIVE DYSKINESIA;

EID: 0037724268     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(03)00170-2     Document Type: Article

References (52)

1. Alexander M.J., Leeman S.E. Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptors. J Comp Neurol. 402:1998;475-500.
2. Andreassen O.A., Jorgensen H.A. The rat model of tardive dyskinesia relationship between vacuous chewing movements and motor activity during acute and long-term haloperidol treatment . Life Sci. 24:1995;2263-2272.
3. Binder E.B., Kinkead B., Owens M.J., Kilts C.D., Nemeroff C.B. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs evidence from animal models of sensorimotor gating . J Neurosci. 21:2001;601-608.
4. Bolden-Watson C., Watson M.A., Murray K.D., Isackson P.J., Richelson F. Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra. J Neurochem. 61:1993;1141-1143.
5. Boudin H., Pelaprat D., Rostene W., Beaudet A. Cellular distribution of neurotensin receptors in rat brain immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor . J Comp Neurol. 373:1996;76-89.
6. Brog J.S., Zahm D.S. Morphologically distinct subpopulations of neurotensin-immunoreactive striatal neurons observed in rat following dopamine depletions and D2 receptor blockade project to the globus pallidus. Neuroscience. 74:1996;805-812.
7. Castel M.N., Morino P., Hokfelt T. Modulation of the neurotensin striatonigral pathway by D1 receptors. Neuroreport. 5:1993;281-284.
8. Castel M.N., Morino P., Nylander I., Terenius L., Hokfelt T. Differential dopaminergic regulation of the neurotensin striatonigral and striatopallidal pathways in the rat. Eur J Pharmacol. 262:1994;1-10.
9. Chakos M.H., Shirakawa O., Lieberman J., Lee H., Bilder R., Tamminga C.A. Striatal enlargement in rats chronically treated with neuroleptic. Biol Psychiatry. 44:1998;675-684.
10. Deutch A.Y., Zahm D.S. The current status of neurotensin-dopamine interactions. Ann NY Acad Sci. 668:1992;232-252.
11. Diana M., Collu M., Mura A., Gessa G.L. Haloperidol-induced vacuous chewing in rats suppression by alpha-methyl-tyrosine . Eur J Pharmacol. 211:1992;415-419.
12. Egan M.F., Hurd Y., Ferguson J., Bachus S.E., Hamid E.H., Hyde T.M. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology. 127:1996;337-345.
13. Fassio A., Evans G., Grisshammer R., Bolam J.F., Mimmack M., Emson P.C. Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody. Neuropharmacology. 39:2000;1430-1442.
14. Ferraro L., Antonelli T., O'Connor W.T., Fuxe K., Soubrié P., Tanganelli S. The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop . J Neurosci. 18:1998;6977-6989.
15. Ferraro L., Tomasini M.C., Fernandez M., Bebe B.W., O'Connor W.T., Fuxe K., Glennon J.C., Tanganelli S., Antonelli T. Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission a dual-probe microdialysis study in intact conscious rat brain . Neuroscience. 102:2001;113-120.
16. Ghaemi S.N., Ko J.Y. Quetiapine-related tardive dyskinesia. Am J Psychiatry. 158:2001;1737.
17. Glenthoj B., Hemmingsen R., Allerup P., Bolwig T.G. Intermittent versus continuous neuroleptic treatment in a rat model. Eur J Pharmacol. 190:1990;275-286.
18. Goedert M., Iversen S.D., Emson P.C. The effects of chronic neuroleptic treatment on neurotensin-like immunoreactivity in the rat central nervous system. Brain Res. 335:1985;334-336.
19. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13:1990;244-254.
20. Hashimoto T., Ross D.E., Gao X.M., Medoff D.R., Tamminga C.A. Mixture of distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia. Psychopharmacology. 132:1998;107-112.
21. Hokfelt T., Broberger C., Xu Z.-Q.D., Sergeyev V., Ubink R., Diez M. Neuropeptides an overview . Neuropharmacology. 39:2000;1337-1356.
22. Holtom P.E., Needham P.L., Bennett G.W., Aspley S. Chronic, but not acute, dosing of antipsychotic drugs alters neurotensin binding in rat brain regions. Br J Pharmacol. 131:2000;990-996.
23. Iversen S.D., Howells R.B., Hughes R.P. Behavioral consequences of long-term treatment with neuroleptic drugs. Adv Biochem Psychopharmacol. 24:1980;305-313.
24. Kane J.M., Smith J.M. Tardive dyskinesia prevalence and risk factors . Arch Gen Psychiatry. 39:1982;473-481.
25. Kelley A.E., Bakshi V.P., Delfs J.M., Lang C.G. Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats pharmacological and regional specificity . Psychopharmacology. 99:1989;542-549.
26. Kinkead B., Binder E.B., Nemeroff C.B. Does neurotensin mediate the effects of antipsychotic drugs? Biol Psychiatry. 46:1999;340-351.
27. Mackay A.V.P. Clinical controversies in tardive dyskinesia. Marsden C.D., Fahn S. Butterworth's international medical reviews: neurology 2: movement disorder. 1982;249-262 Butterworth Scientific, London.
28. McCormick S.E., Stoessl A.J. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia. Neuroscience. 112:2002;851-859.
29. Merchant K.M., Bush L.G., Gibb J.W., Hanson G.R. Neurotensin dopamine interactions in the substantia nigra of the rat. J Pharmacol Exp Ther. 255:1990;775-780.
30. Merchant K.M., Dobner P.R., Dorsa D.M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J Neurosci. 12:1992;652-663.
31. Merchant K.M., Hanson G.R., Dorsa D.M. Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine comparison with acute haloperidol effects . J Pharmacol Exp Ther. 269:1994;806-812.
32. Modestin J., Stephan P.L., Erni T., Umari T. Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine to tardive dyskinesia. Schizophr Res. 42:2000;223-230.
33. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 2nd ed: 1986;Academic Press, New York.
34. Pisa M. Motor functions of the striatum in the rat critical role of the lateral region in tongue and forelimb reaching . Neuroscience. 24:1988;453-463.
35. Radke J.M., MacLennan A.J., Bienfield M.C., Bissette G., Nemeroff C.B., Vincent S.R., Fibiger H.C. Effects of short- and long-term haloperidol administration and withdrawal on regional brain cholecystokinin and neurotensin concentrations in the rat. Brain Res. 480:1989;178-183.
36. Radke J.M., Owens M.J., Ritchie J.C., Nemeroff C.B. Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions. Proc Natl Acad Sci USA. 95:1998;11462-11464.
37. Salamone J.D., Johnson J., McCullough L.D., Steinpreis R.E. Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat. Psychopharmacology. 102:1990;529-534.
38. Stoessl A.J. Effects of neurotensin in a rodent model of tardive dyskinesia. Neuropharmacology. 34:1995;457-462.
39. 2 receptor antagonists . Psychopharmacology. 98:1989;372-379.
40. Stoessl A.J., James K.A., Napier B.J. The neurotensin antagonist SR48692 fails to modify the behavioural responses to a dopamine D1 receptor agonist in the rat. Neuropharmacology. 36:1997;93-99.
41. Stoessl A.J., Polanski E., Frydryszak H. The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. Mov Disord. 8:1993;445-452.
42. Stoessl A.J., Rajakumar N. Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia. Synapse. 24:1996;256-261.
43. Stoessl A.J., Szczutkowski E. Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat. Brain Res. 558:1991;289-295.
44. Szigethy E., Beaudet A. Correspondence between high affinity 125I-neurotensin binding sites and dopaminergic neurons in the rat substantia nigra and ventral tegmental area a combined radioautographic and immunohistochemical light microscopic study . J Comp Neurol. 279:1989;128-137.
45. Tamminga C.A., Dale J.M., Goodman L., Kaneda H., Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia in three rat strains. Psychopharmacology. 102:1990;474-478.
46. Trugman J.M., Hubbard C.A., Bennett J.P. Jr. Dose-related effects of continuous levodopa infusion in rats with unilateral lesions of the substantia nigra. Brain Res. 725:1996;177-183.
47. Uhl G.R., Kuhar M.J. Chronic neuroleptic treatment enhances neurotensin receptor binding in human and rat substantia nigra. Nature. 309:1984;350-352.
48. Van Kampen J.M., Stoessl A.J. Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia. Neuroscience. 101:2000;629-635.
49. Vincent J.P., Mazella J., Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci. 20:1999;302-309.
50. Waddington J.L., Cross A.J., Gamble S.J., Bourne R.C. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months neuroleptic treatment. Science. 220:1983;530-532.
51. Walker N., Lepee-Lorgeoux I., Fournier J., Betancur C., Rostene W., Ferrara P., Caput D. Tissue distribution and cellular localization of the levocabastine-sensitive neurotensin receptor mRNA in adult rat brain. Brain Res Mol Brain Res. 57:1998;193-200.
52. Yassa R., Jeste D.V. Gender differences in tardive dyskinesia a critical review of the literature . Schizophr Bull. 18:1992;701-715.